Identification and characterization of gut microbial bioactive molecules that determine predisposition to autoimmune disease and atopy

确定自身免疫性疾病和特应性倾向的肠道微生物生物活性分子的鉴定和表征

基本信息

  • 批准号:
    9238030
  • 负责人:
  • 金额:
    $ 68.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-04-01 至 2021-03-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT We know that the gut microbiome functions as an accessory organ system that plays critical roles in human digestion; the production of essential vitamins, neurotransmitters, and other small molecules; and in the regulation of the immune system. We also know that changes in the gut microbiota can lead to disease, especially inflammatory bowel disease and related inflammatory disorders. However, we know very little about the molecules and mechanisms that connect gut microbiota to these diseases. As the bacteria in the gut microbiota sense and respond to their environment with small molecules, it's likely that some of these molecules are key regulators of both pro-inflammatory and anti-inflammatory responses. This project seeks to identify these molecules and the mechanisms by which they operate. The project stems from a rich data set (DIABIMMUNE) that revealed a number of robust correlations between the appearance, or disappearance, of members of the gut microbiota and the development of dysregulated immune responses and disease in infants with genetic pre-disposition to type 1 diabetes. We will focus on ~40 strains that appear to play outsize roles in disease progression to discover what pro- or anti-inflammatory small molecule signals they produce. In Specific Aim 1 we will culture patient-derived strains of these bacteria under a variety of conditions, capture the small molecules produced, and measure their ability to regulate a pro-inflammatory signal (TNFalpha) and an anti- inflammatory signal (IL-10). The most potent and selective regulators will advance to Specific Aim 2 in which bioassay-guided fractionation will guide the isolation of active molecules, which will then be structurally characterized with spectroscopic (both nuclear magnetic resonance and mass spectrometry) and imaging (X-ray diffraction) techniques. With known molecules linked to confirmed biological activity in hand, we will prioritize hits based on their presence in the DIABIMMUNE stool samples, which we have archived. Only bioactive molecules present in human samples will be analyzed in specific Aim 3 to determine mechanism. Because the signaling pathways through which these molecules exert their biological effects are complex, we will employ a specially designed and newly implemented assay that simultaneously measures more than 50 transcription factors that regulate inflammation, immunity, metabolism and cell stress. By profiling transcription factor activity and comparing to known compounds, we will be able to classify molecules based on their activity profiles. We will further characterize their mechanism of action using a variety of functional assays on both patient derived myeloid cells as well as colonic and ileal mucosa cell lines that develop into four distinct cell types that form three-dimensional structures including crypts covered by a secreted mucus layer. At the end of the pipeline formed by these three specific aims, small molecules that regulate immune responses along annotated pathways will be known, and this identification of both molecule and mechanism will provide insights into both basic biology and potential therapeutic interventions.
抽象的 我们知道,肠道微生物组作为辅助器官系统,在人类健康中发挥着关键作用。 消化;生产必需的维生素、神经递质和其他小分子;并在 免疫系统的调节。我们还知道肠道微生物群的变化会导致疾病, 特别是炎症性肠病和相关的炎症性疾病。然而我们对此知之甚少 将肠道微生物群与这些疾病联系起来的分子和机制。由于肠道内的细菌 微生物群通过小分子感知环境并做出反应,其中一些分子很可能 是促炎和抗炎反应的关键调节因子。该项目旨在确定 这些分子及其运作机制。该项目源于丰富的数据集 (DIABIMMUNE)揭示了许多存在或消失之间的强大相关性 肠道微生物群成员以及婴儿免疫反应失调和疾病的发展 具有 1 型糖尿病的遗传倾向。我们将重点关注约 40 种似乎在 疾病进展,以发现它们产生什么促炎或抗炎小分子信号。具体来说 目标 1 我们将在各种条件下培养源自患者的这些细菌菌株,捕获小的 分子产生,并测量其调节促炎信号(TNFα)和抗炎信号的能力 炎症信号(IL-10)。最有效和最有选择性的监管机构将推进到具体目标 2,其中 生物测定引导的分馏将指导活性分子的分离,然后在结构上进行分离 通过光谱(核磁共振和质谱)和成像(X 射线)进行表征 衍射)技术。有了与手头已确认的生物活性相关的已知分子,我们将优先考虑 根据我们已存档的 DIABIMMUNE 粪便样本中的存在情况进行命中。仅有生物活性 人类样本中存在的分子将在特定目标 3 中进行分析以确定机制。因为 这些分子发挥其生物效应的信号传导途径很复杂,我们将采用 专门设计和新实施的检测方法可同时测量 50 多个转录 调节炎症、免疫、新陈代谢和细胞应激的因素。通过分析转录因子活性 与已知化合物相比,我们将能够根据分子的活性特征对分子进行分类。我们 将使用对两种患者来源的多种功能测定进一步表征其作用机制 骨髓细胞以及结肠和回肠粘膜细胞系发育成四种不同的细胞类型 三维结构,包括被分泌的粘液层覆盖的隐窝。在管道的末端 由这三个特定目标形成,沿着注释调节免疫反应的小分子 途径将是已知的,并且对分子和机制的识别将提供对两者的见解 基础生物学和潜在的治疗干预措施。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jon Clardy其他文献

Jon Clardy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jon Clardy', 18)}}的其他基金

Identification and characterization of gut microbial bioactive molecules that determine predisposition to autoimmune disease and atopy
确定自身免疫性疾病和特应性倾向的肠道微生物生物活性分子的鉴定和表征
  • 批准号:
    10239455
  • 财政年份:
    2017
  • 资助金额:
    $ 68.65万
  • 项目类别:
Identification and characterization of gut microbial bioactive molecules that determine predisposition to autoimmune disease and atopy
确定自身免疫性疾病和特应性倾向的肠道微生物生物活性分子的鉴定和表征
  • 批准号:
    9889899
  • 财政年份:
    2017
  • 资助金额:
    $ 68.65万
  • 项目类别:
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates
来自巴西无脊椎动物细菌共生体的新型治疗剂
  • 批准号:
    8902965
  • 财政年份:
    2014
  • 资助金额:
    $ 68.65万
  • 项目类别:
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates
来自巴西无脊椎动物细菌共生体的新型治疗剂
  • 批准号:
    8785542
  • 财政年份:
    2014
  • 资助金额:
    $ 68.65万
  • 项目类别:
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates
来自巴西无脊椎动物细菌共生体的新型治疗剂
  • 批准号:
    9335718
  • 财政年份:
    2014
  • 资助金额:
    $ 68.65万
  • 项目类别:
Genomic approaches of discovery broad-spectrum antimicrobial agents
发现广谱抗菌药物的基因组方法
  • 批准号:
    8233437
  • 财政年份:
    2011
  • 资助金额:
    $ 68.65万
  • 项目类别:
STRUCTURAL AND MECHANISTIC STUDIES OF THE PANTOCIN A BIOSYNTHESIS
全解菌素A生物合成的结构和机理研究
  • 批准号:
    7955137
  • 财政年份:
    2009
  • 资助金额:
    $ 68.65万
  • 项目类别:
Genomic approaches of discovery broad-spectrum antimicrobial agents
发现广谱抗菌药物的基因组方法
  • 批准号:
    7669772
  • 财政年份:
    2009
  • 资助金额:
    $ 68.65万
  • 项目类别:
Chemical biology of bacterial symbionts
细菌共生体的化学生物学
  • 批准号:
    8503293
  • 财政年份:
    2008
  • 资助金额:
    $ 68.65万
  • 项目类别:
Molecule-to-gene approaches to new natural products
新天然产物的分子到基因方法
  • 批准号:
    7684744
  • 财政年份:
    2008
  • 资助金额:
    $ 68.65万
  • 项目类别:

相似国自然基金

本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目

相似海外基金

Environmental Exposures & Sleep in the Nurses' Health Study 3
环境暴露
  • 批准号:
    10677271
  • 财政年份:
    2023
  • 资助金额:
    $ 68.65万
  • 项目类别:
Puerto Rican Obesity Intervention for Men
波多黎各男性肥胖干预
  • 批准号:
    10660433
  • 财政年份:
    2023
  • 资助金额:
    $ 68.65万
  • 项目类别:
Fathers and Children Exercising Together (FACEiT)
父亲和孩子一起锻炼 (FACEiT)
  • 批准号:
    10789457
  • 财政年份:
    2023
  • 资助金额:
    $ 68.65万
  • 项目类别:
Free Time 4 Wellness
空闲时间 4 健康
  • 批准号:
    10719761
  • 财政年份:
    2023
  • 资助金额:
    $ 68.65万
  • 项目类别:
Making Healthy Habits Stick: Extended Contact Interventions to Promote Long Term Physical Activity in African American Cancer Survivors
养成健康习惯:延长接触干预措施以促进非裔美国癌症幸存者的长期身体活动
  • 批准号:
    10821052
  • 财政年份:
    2023
  • 资助金额:
    $ 68.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了